A Phase 1/2 Study of the Combination of RDEA119 and Sorafenib in Patients With Advanced Cancer.

Trial Profile

A Phase 1/2 Study of the Combination of RDEA119 and Sorafenib in Patients With Advanced Cancer.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 20 Oct 2016

At a glance

  • Drugs Refametinib (Primary) ; Sorafenib (Primary)
  • Indications Breast cancer; Colorectal cancer; Head and neck cancer; Malignant melanoma; Solid tumours; Thyroid cancer
  • Focus Adverse reactions
  • Sponsors Bayer
  • Most Recent Events

    • 07 Dec 2015 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
    • 01 Sep 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 08 Nov 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top